Most travel brands have a point of view of sorts on their recovery efforts.
These plans are subject to many things, such as the demand from travelers, availability of supply and the status of partnerships that existed before the coronavirus pandemic hit the sector.
How these strategies are put into place can be determined by the players involved and gauging the enthusiasm of travelers to get on the road (“pent-up demand” is a phrase being used a lot in early-2021).
But a number of variables are out of control of traveler-facing brands and the technology providers behind the scenes.
This area of the recovery process is centered on the work of health officials and the availability and administering of vaccines.
We spoke to Florian Krammer, professor of vaccinology in the Department of Microbiology at Mount Sinai Innovation Partners in New York City, during the PhocusWire Pulse: Safer & Seamless event on February 23, 2021.
In the interview we discuss vaccines, antibody testing and, crucially for the travel industry, the challenges and process that different segments are having to consider as they bring back travelers to their products.
The full interview is listed below:
PhocusWire Pulse: Safer & Seamless – Professor Florian Krammer